Comparative Pharmacology
Head-to-head clinical analysis: CLAFORAN versus ULTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLAFORAN versus ULTRACEF.
CLAFORAN vs ULTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefadroxil, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis. It is bactericidal against susceptible organisms.
1-2 g IV/IM every 8 hours. Maximum dose: 12 g/day in divided doses.
250 mg orally every 6 hours or 500 mg orally every 12 hours for uncomplicated urinary tract infections; 1 g orally every 12 hours for complicated urinary tract infections.
None Documented
None Documented
0.8-1.4 hours in normal renal function (prolonged to 11-30 hours in severe renal impairment, CrCl <10 mL/min). No clinically relevant accumulation with standard dosing in renal impairment with dose adjustment.
0.5–1.2 hours in normal renal function; prolonged to 2–4 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal <10%.
Approximately 90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; less than 1% is excreted in feces via biliary elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic